Your browser doesn't support javascript.
loading
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans.
Bauman, Jonathan N; Doran, Angela C; King-Ahmad, Amanda; Sharma, Raman; Walker, Gregory S; Lin, Jian; Lin, Tsung H; Telliez, Jean-Baptiste; Tripathy, Sakambari; Goosen, Theunis C; Banfield, Christopher; Malhotra, Bimal K; Dowty, Martin E.
Afiliação
  • Bauman JN; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Phar
  • Doran AC; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Phar
  • King-Ahmad A; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Phar
  • Sharma R; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Phar
  • Walker GS; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Phar
  • Lin J; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Phar
  • Lin TH; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Phar
  • Telliez JB; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Phar
  • Tripathy S; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Phar
  • Goosen TC; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Phar
  • Banfield C; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Phar
  • Malhotra BK; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Phar
  • Dowty ME; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Phar
Drug Metab Dispos ; 50(8): 1106-1118, 2022 08.
Article em En | MEDLINE | ID: mdl-35701182
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirimidinas / Sulfonamidas / Dermatite Atópica / Inibidores de Janus Quinases Limite: Humans / Male Idioma: En Revista: Drug Metab Dispos Assunto da revista: FARMACOLOGIA Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirimidinas / Sulfonamidas / Dermatite Atópica / Inibidores de Janus Quinases Limite: Humans / Male Idioma: En Revista: Drug Metab Dispos Assunto da revista: FARMACOLOGIA Ano de publicação: 2022 Tipo de documento: Article